Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022)
Lexicon Pharmaceuticals' (LXRX) quarterly Non Operating Investment Income came in at -$27000.0 in Q1 2022, down 150.94% on a QoQ basis from $53000.0 in Q2 2010.
Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 2 years of Non Operating Investment Income data on file, last reported at -$27000.0 in Q1 2022.
- On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to -$27000.0 in Q1 2022; TTM through Mar 2022 was -$27000.0, a N/A change from a year earlier, with the FY2010 full-year figure at $141000.0, down 87.98% from the prior year.
- Non Operating Investment Income for Q1 2022 stood at -$27000.0, down from $53000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for LXRX reached as high as -$27000.0 in Q1 2022 and fell as low as -$27000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 922.55 Mn | 751.90 Mn | 20.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -27,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Jun 30, 2010 | 53,000.00 |
| Jun 30, 2010 | 53,000.00 |